Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART

This study has been completed.
Sponsor:
Collaborators:
National Institutes of Health (NIH)
Merck Sharp & Dohme Corp.
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
David Margolis, MD, University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier:
NCT01319383
First received: March 17, 2011
Last updated: June 3, 2016
Last verified: June 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2016
  Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):